Stocktoria
NATURES SUNSHINE PRODUCTS INC NATR
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2009-06-25
NATURES SUNSHINE PRODUCTS INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $480.1M | $454.4M | $445.3M | $421.9M | $444.1M | $385.2M | $362.2M | $364.8M | $342.0M | $341.2M |
| Gross profit | $347.7M | $324.7M | $321.1M | $299.8M | $328.6M | $283.9M | $268.3M | $269.1M | $251.0M | $250.2M |
| R&D expense | $1.9M | $1.7M | $1.6M | $1.5M | $1.4M | $1.5M | $2.1M | $2.8M | $3.4M | $3.2M |
| SG&A expense | $178.4M | $164.0M | $167.1M | $153.1M | $154.1M | $131.3M | $128.7M | $138.4M | $129.6M | $120.3M |
| Operating income | $24.7M | $20.1M | $18.7M | $16.3M | $34.7M | $21.5M | $16.1M | $5.4M | $1.4M | $10.0M |
| Interest expense | — | — | $69,000 | $249,000 | $250,000 | $102,000 | $43,000 | $387,000 | $289,000 | $16,000 |
| Income tax | $9.4M | $10.5M | $3.8M | $14.7M | $1.6M | -$137,000 | $8.7M | $4.4M | $17.0M | $8.6M |
| Net income | $19.5M | $7.7M | $15.1M | -$390,000 | — | — | — | — | — | — |
| EPS (diluted) | $1.06 | $0.40 | $0.77 | $-0.02 | $1.42 | $1.07 | $0.34 | $-0.04 | $-0.69 | $0.11 |
| Operating cash flow | $35.3M | $25.3M | $41.2M | $710,000 | $34.6M | $37.7M | $8.5M | $21.8M | $10.5M | $3.4M |
| Free cash flow | $28.8M | $14.3M | $30.7M | -$6.9M | $27.9M | $32.8M | $3.4M | $17.0M | $5.0M | -$7.6M |
| Cash & equivalents | $93.9M | $84.7M | $82.4M | $60.0M | $86.2M | $92.1M | $53.6M | $50.6M | $42.9M | $32.3M |
| Inventory | $68.3M | $59.4M | $66.9M | $67.9M | $60.9M | $47.7M | $46.7M | $42.0M | $44.0M | $47.6M |
| Total assets | $261.1M | $240.9M | $249.8M | $229.8M | $258.9M | $249.5M | $213.1M | $193.0M | $195.2M | $205.6M |
| Total liabilities | $99.6M | $79.9M | $90.2M | $82.7M | $97.5M | $92.3M | $83.6M | $72.4M | $75.5M | $73.2M |
| Shareholders' equity | $161.6M | $161.0M | $159.5M | $147.0M | $161.4M | $157.2M | $129.4M | $120.6M | $119.7M | $132.4M |
Growth · year-over-year · Revenue CAGR 3.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +5.7% | +2.0% | +5.5% | -5.0% | +15.3% | +6.3% | -0.7% | +6.7% | +0.3% | +5.1% |
| Net income growth | +153.7% | -49.0% | — | — | — | — | — | — | — | — |
| EPS growth | +165.0% | -48.1% | — | -101.4% | +32.7% | +214.7% | — | — | -727.3% | -85.7% |
| Free cash flow growth | +101.3% | -53.4% | — | -124.8% | -14.7% | +851.9% | -79.8% | +238.4% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.